General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Alynylam Pharmaceuticals(MODEST), Bayer Healthcare Pharmaceuticals(MODEST), Bristol-Myers Squibb Company (MODEST), Ionis Pharmaceuticals(MODEST), Novartis Corporation(MODEST), Regeneron Pharmaceuticals(MODEST), River 2 Renal Corporation(MODEST) SPEAKER'S BUREAU: Abbott Laboratories(MODEST), Alkem Metabolics(MODEST), AstraZeneca Pharmaceuticals(MODEST), Blue Ocean Scientific Solutions Ltd.(MODEST), Boehringer Ingelheim Pharmaceuticals, Inc(MODEST), Canadian Medical and Surgical Knowledge(MODEST), Emcure Pharmaceuticals Ltd.(MODEST), Eris Lifesciences(MODEST), European Academy of CME(MODEST), Hikma Pharmaceuticals(MODEST), Imagica Health(MODEST), Intas Pharmacueticals(MODEST), J.B. Chemicals & Pharmaceuticals Ltd.(MODEST), Lupin Pharmaceuticals, Inc(MODEST), ProAdWise Communications(MODEST), Radcliffe Cardiology(MODEST), Sun Pharmaceuticals(MODEST), The Corpus(MODEST), Translation Research Group(MODEST), Translational Medicine Academy(MODEST) RESEARCH/RESEARCH GRANTS: Amgen Inc.(SIGNIFICANT), Novartis Corporation(SIGNIFICANT) OTHER FINANCIAL BENEFIT: AstraZeneca Pharmaceuticals(SIGNIFICANT), GSK(SIGNIFICANT), Cardurion(MODEST), Cytokinetics(SIGNIFICANT), Bayer Healthcare Pharmaceuticals(MODEST), KBP Biosciences(MODEST), Global Clinical Trial Partners Ltd. (GCTP)(SIGNIFICANT)

View Full Disclosure